Literature DB >> 9374226

Coexpression of interleukin-8 receptors in head and neck squamous cell carcinoma.

B L Richards1, R J Eisma, J D Spiro, R L Lindquist, D L Kreutzer.   

Abstract

BACKGROUND: Interleukin 8 (IL-8) is an important cytokine involved in tumor growth and angiogenesis in a variety of malignancies. We hypothesize that IL-8 plays an important role in the cellular proliferation and angiogenesis seen in head and neck squamous cell carcinoma (HNSCC) and set out to identify its receptors, IL-8RA and IL-8RB.
METHODS: Immunohistochemical analysis was performed on specimens from 38 HNSCC patients with stage I to IV disease and control tissues.
RESULTS: All of cancer specimens demonstrated positive staining for IL-8RA. The IL-8RA staining of microvessel endothelial cells was seen in 51%. The IL-8RB pattern was similar to the IL-8RA pattern in that 97% of cancer sections demonstrated positive cancer cell staining, and 74% of the specimens demonstrated positive staining for microvessel endothelial cells.
CONCLUSION: Our studies demonstrate that IL-8 receptors are expressed by cancer cells and microvessel endothelial cells in HNSCC, suggesting that IL-8 may act in an autocrine/paracrine fashion to stimulate cellular proliferation and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374226     DOI: 10.1016/s0002-9610(97)00165-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  22 in total

1.  High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma.

Authors:  Liang Han; Bin Jiang; Hao Wu; Xudong Wang; Xiaojun Tang; Jianfei Huang; Jin Zhu
Journal:  Med Oncol       Date:  2012-01-25       Impact factor: 3.064

2.  Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.

Authors:  K I Amiri; H C Ha; M E Smulson; A Richmond
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 3.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

4.  The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma.

Authors:  H Haghnegahdar; J Du; D Wang; R M Strieter; M D Burdick; L B Nanney; N Cardwell; J Luan; R Shattuck-Brandt; A Richmond
Journal:  J Leukoc Biol       Date:  2000-01       Impact factor: 4.962

Review 5.  CXC chemokines in cancer angiogenesis and metastases.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

6.  Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Brigitte Gomperts; Ying Ying Xue; Kurt Hong; Javier Mestas; Abbas Ardehali; Borna Mehrad; Rajan Saggar; Joseph P Lynch; David J Ross; Robert M Strieter
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

7.  Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells.

Authors:  B B Moore; D A Arenberg; K Stoy; T Morgan; C L Addison; S B Morris; M Glass; C Wilke; Y Y Xue; S Sitterding; S L Kunkel; M D Burdick; R M Strieter
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

8.  Salivary level of interleukin-8 in oral precancer and oral squamous cell carcinoma.

Authors:  Silky Rajesh Punyani; Ramhari Shankarrao Sathawane
Journal:  Clin Oral Investig       Date:  2012-04-18       Impact factor: 3.573

9.  Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma.

Authors:  Jun Pu Wang; Wan Ming Hu; Kuan Song Wang; Bai Hua Luo; Chang Wu; Zhi Hong Chen; Geng Qiu Luo; Yu Wu Liu; Qin Lai Liu; Jun Yu; Jing He Li; Ji Fang Wen
Journal:  Exp Ther Med       Date:  2012-05-07       Impact factor: 2.447

10.  Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.

Authors:  Bhawna Sharma; Dhananjay M Nawandar; Kalyan C Nannuru; Michelle L Varney; Rakesh K Singh
Journal:  Mol Cancer Ther       Date:  2013-03-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.